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ABSTRACT
Background/aims With the increased efficacy of current
therapy for wet age-related macular degeneration
(AMD), better ways to detect wet AMD are needed. This
study was designed to test the ability of three-
dimensional contrast threshold Amsler grid (3D-CTAG)
testing to distinguish wet AMD from dry AMD.
Methods Conventional paper Amsler grid and 3D-CTAG
tests were performed in 90 eyes: 63 with AMD (34 dry,
29 wet) and 27 controls. Qualitative comparisons were
based upon the three-dimensional shapes of central visual
field (VF) defects. Quantitative analyses considered the
number and volume of the three-dimensional defects.
Results 25/34 (74%) dry AMD and 6/29 (21%) wet
AMD eyes had no distortions on paper Amsler grid. Of
these, 5/25 (20%) dry and 6/6 (100%) wet (p¼0.03)
AMD eyes exhibited central VF defects with 3D-CTAG.
Wet AMD displayed stepped defects in 16/28 (57%)
eyes, compared with only 2/34 (6%) of dry AMD eyes
(p¼0.002). All three volumetric indices of VF defects
were two- to four-fold greater in wet than dry AMD
(p<0.006). 3D-CTAG had 83.9% positive and 90.6%
negative predictive values for wet AMD.
Conclusions 3D-CTAG has a higher likelihood of
detecting central VF defects than conventional Amsler
grid, especially in wet AMD. Wet AMD can be
distinguished from dry AMD by qualitative and
quantitative 3D-CTAG criteria. Thus, 3D-CTAG may be
useful in screening for wet AMD, quantitating disease
severity, and providing a quantitative outcome measure
of therapy.
INTRODUCTION
Throughout the western world, age-related
macular degeneration (AMD) is the leading cause of
blindness in persons older than 65 years of age.1e3
An estimated 1.75 million Americans and 3.35
million Europeans have AMD, with a prevalence of
exudative AMD approaching 8.29/100 in Caucasian
persons older than 80 years.4 By 2020, this number
is expected to grow by more than 50%.4 AMD
currently accounts for 54.4% of blindness and
22.9% of low vision among white persons, 14.3% of
blindness and 14.1% of low vision among Hispanic
persons, and 4.4% of blindness and 3.2% of low
vision among black persons.5
Traditional screening for AMD has included the
paper Amsler grid, despite low sensitivity and high
false-negative readings, especially concerning
scotomas of 68 or less.6 7 With the advent of anti-
vascular endothelial growth factor (VEGF) therapy
and the prospect of other more potent treatments,
there is an increased need for earlier detection of
treatable disease and a way to quantitatively
monitor its response to therapy.8e10
Three-dimensional computer-automated threshold
Amsler grid (3D-CTAG) testing improves upon the
traditional paper Amsler grid by assessing central
visual ﬁelds (VF) at several contrast sensitivity
levels, not just one.11 Clinical studies have found
non-invasive 3D-CTAG testing to be fast (<5 min
per eye), easy (intuitive use of ﬁnger), accurate
(<18) and comprehensive.12e15 Conditions such as
glaucoma, ocular hypertension, macular oedema
and ethambutol-induced optic neuropathy have
successfully been quantitatively characterised with
this approach.11e15 These previous studies demon-
strated a high reproducibility (>90%) of 3D-CTAG
detection of central VF defects in repeat testing.14
Previous studies in AMD16 have shown that the
central VF defects detected with 3D-CTAG testing
correspond to anatomical defects seen on ﬂuores-
cein angiography. To date, however, 3D-CTAG has
only qualitatively (not quantitatively) characterised
non-exudative (dry) and exudative (wet) AMD.16
What has been lacking is a quantitative index of
central VF defects in AMD. 3D-CTAG testing and
analysis may provide a rapid, reproducible and non-
invasive test useful for screening as well as moni-
toring patients with AMD.
This study therefore aimed to further charac-
terise dry and wet AMD using 3D-CTAG using
both qualitative as well as quantitative assessments
of central VF defects. The objective was to deter-
mine the potential utility of 3D-CTAG to screen for
wet AMD as well as provide insight as to whether
this test might be used to quantitatively monitor
the response to therapy. It was hypothesised that
3D-CTAG would increase the sensitivity for
detection of wet AMD and provide quantitative
indices that would distinguish wet from dry AMD.
MATERIALS AND METHODS
Subjects
This cross-sectional study included 63 eyes of 43
patients with AMD. Eyes from age-matched
controls without maculopathy (n¼27) were also
tested, bringing the total study population to 90
eyes in 70 subjects. Of the 63 eyes with AMD, there
were 19 men (44%) and 24 women (56%), with
a mean age of 77.4610 years (values are mean6SD).
Of these, 34 were diagnosed with dry AMD (mean
age 75.969.5 years) and 29 eyes were diagnosed
with wet AMD (mean age 77.769.9 years) (p¼0.49).
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Mean visual acuity (VA) in dry AMD eyes was logarithm of the
minimum angle of resolution (logMAR) 0.20 (range 0.00e0.85)
(Snellen 20/32), while VA in wet AMD eyes was logMAR 0.42
(range 0.00e1.60) (Snellen 20/53) (p¼0.009). There were
27 control eyes without maculopathy (mean age 68.0610.9 years)
who had a mean VA of logMAR 0.12 (range 0.00e0.40)
(Snellen 20/28).
All subjects were evaluated by a single Vitreo-Retinal Surgeon
(JS) using physical examination and diagnostic testing (ﬂuores-
cein angiography and combined optical coherence tomography
(OCT)/scanning laser ophthalmoscopy (SLO)) in each case. The
clinical diagnosis for study entry was clear-cut evidence of
exudative AMD (choroidal neovascularisation with clinically
signiﬁcant leakage in each case) or clear-cut absence of any
evidence of exudative disease. No questionable cases were included.
Fundus photography and ﬂuorescein angiography were
performed (Topcon Imagenet 2000; Topcon, Tokyo, Japan) to
diagnose and classify each eye as dry (drusen, chorio-retinal
atrophy and pigment clumping) or wet (choroidal neovascular-
isation, serous elevation of the macula or retinal pigment
epithelium detachment) AMD. OCT was performed with the
spectral-domain combined OCT-SLO (OPKO/OTI Inc., Miami,
Florida, USA) to further characterise and conﬁrm the diagnosis.
Six radial scans through the centre of the fovea were performed
with additional lines through the upper and lower arcades, as
well as through the optic disc.
Eyes diagnosed with geographic atrophy and disciform scar-
ring were excluded, but previous treatments with intra-vitreal
injections was not an exclusion criterion. In 20 subjects with
AMD in both eyes, each eye was included in the appropriate
diagnostic group. To determine whether 3D-CTAG might be
useful as a screening test with which to distinguish between dry
and wet AMD these two groups were compared.
Central VF evaluations with 3D-CTAG
Each subject was evaluated without pupil dilation after
measuring best corrected VA with habitual eyewear. Refraction
was not performed prior to evaluation. Conventional central VF
testing employed a paper Amsler grid of white lines on a black
background held at a distance of 30 cm. The presence of either
metamorphopsia or a central VF disturbance was conveyed to
the evaluator and recorded. Any abnormality (distortion or
scotoma) identiﬁed by the patient using their ﬁnger to outline
the abnormalities directly on the touch screen was recorded.
Each 3D-CTAG contrast level represents a horizontal cut
through the ‘hill-of-vision’ and evaluates the central 258 ﬁeld of
vision (radially from the centre of ﬁxation).17e19 The ﬁve indi-
vidual contrast level maps are aligned along the z-axis (which
included 5%, 10%, 20%, 40% and 100% contrast) by the
computer program to produce a three-dimensional topographical
map of the patient’s contrast sensitive central VF. Testing
protocol has been previously described.11 13 16
Indices used for the quantitative analysis of central VF deﬁcits
included: number of defects per eye; percentage of the hill-of-
vision volume lost compared with a normal/unimpaired hill-of-
vision; lost area grade (LAG; scotoma area at lowest tested
contrast sensitivity level/scotoma area at highest tested contrast
sensitivity level) 3 scotoma depth (%); preserved area grade
(PAG; intact VF area at highest tested contrast sensitivity level/
intact VF area at lowest tested contrast sensitivity level) 3
scotoma depth (%); and difference area grade (DAG; DAG¼
|PAGeLAG|), which is the absolute value of the difference
between PAG and LAG as a means of expressing the symmetry
between them. Evaluation of ﬁxation was determined by the
correlation between LAG (ﬁxation independent) and total slope
(ﬁxation dependent). Fixation was achieved with less than 5%
variability between LAG and total slope (r¼0.95, p<0.001, 95%
CI 0.918 to 0.970).
VA was determined using the logMAR scale and subsequently
reconverted to the corresponding Snellen fraction. For compar-
ison of means values between dry and wet AMD eyes, the least
square means and standard errors were obtained using general-
ised estimating equations (GEE) that were adjusted for the
correlation between eyes within a patient. Logistic regression
analyses were also modelled to adjust for repeated patient.
Correlation analyses for combined wet and dry AMD eyes were
performed using patient averaged data values. SAS v9.2 (SAS
Institute, Cary, North Carolina, USA) was used for all analyses.
RESULTS
Sensitivity of 3D-CTAG
Paper Amsler grid testing revealed VF defects in 23/29 (79%) wet
AMD eyes and 9/34 (26%) dry AMD eyes. Among the eyes that
did not demonstrate visual defects on the traditional paper
Amsler grid, 6/6 (100%) of the wet AMD eyes (p¼0.03, signed
rank sum test) and 5/25 (20%) dry AMD eyes (p¼0.06, signed
rank sum test) exhibited defects with 3D-CTAG. Tables 1 and 2
display the sensitivities for detection of dry and wet AMD using
the traditional paper Amsler grid and the 3D-CTAG, respec-
tively. Figure 1 compares the traditional paper Amsler grid and
the 3D-CTAG with respect to test results in dry and wet AMD,
revealing a greater detection rate of abnormal ﬁndings in wet
AMD (29/29 eyes; 100%) and dry AMD (14/34 eyes; 41%) using
3D-CTAG compared with paper Amsler grid testing. Control
eyes without maculopathy (n¼27) did not have central VF
defects on 3D-CTAG testing.
Qualitative analysis of 3D-CTAG in dry versus wet AMD
Dry AMD (ﬁgure 2) exhibited uniform (steep-walled; ie, same
area of VF defect observed at all ﬁve contrast levels), cylindrical,
three-dimensional defects in 12/14 (86%) eyes. Partial defects
(abnormalities detected at low contrast levels that are absent at
higher contrast levels) were evident in the remaining 2/14 (14%)
dry AMD eyes.
Ninety-seven per cent (28/29) of wet AMD eyes displayed
abnormalities at all ﬁve contrast levels. Of the 28 wet AMD eyes
that had visual defects at all contrast levels, 16/28 (57%) had
larger visual defects at low levels of contrast with smaller
cylindrical defects at higher levels of contrast. As shown in
Table 1 Sensitivity for detection of age-related macular degeneration
(AMD) with traditional paper Amsler grid testing
Paper Amsler grid Wet AMD Dry AMD Total
Visual defects 23 9 32
No visual defect 6 25 31
Total 29 34 63
Sensitivity (%) 79 26
Table 2 Sensitivity for detection of age-related macular degeneration
(AMD) with three-dimensional contrast threshold Amsler grid (3D-CTAG)
testing
3D-CTAG Wet AMD Dry AMD Total
Visual defect 29 14 43
No visual defect 0 20 20
Total 29 34 63
Sensitivity (%) 100 41
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ﬁgure 3, these eyes had large central VF disturbances at low
contrast levels (high contrast sensitivity) with a step-down
progression to smaller cylindrical defects at increasing contrast
levels (small central absolute scotoma with surrounding relative
scotoma, or non-uniform cylindrical central VF abnormalities).
VF defects in the remaining 12/28 (43%) wet AMD eyes
remained cylindrical at all ﬁve tested levels (16/28 vs 12/28
p¼0.45, c2 test for equal proportions) meaning there was no
increase in the area of central VF abnormalities at lower contrast
levels.
Quantitative analysis of 3D-CTAG in dry versus wet AMD
One-hundred per cent of wet AMD eyes had at least one central
VF defect and 14% had more than one defect. In contrast, only
41% of dry AMD eyes had a single defect, and only 3% had more
than one defect. The mean number of defects observed with 3D-
CTAG was 0.44+0.56 (s.d. for the upper end) and 0.44"0.44 (s.
d. for the lower end) versus 1.2460.79 for wet AMD (p<0.001,
GEE).
The mean LAG, which characterises the area of the three-
dimensional defect with respect to the lowest and highest
contrast sensitivity levels, was 29.5 %+41.7% (s.d. for the upper
end) and 29.5%"29.5% (s.d. for the lower end) for dry AMD
versus 66.7630.9% for wet AMD (p<0.001, GEE). The mean
PAG, which characterises the area of the preserved VF with
respect to the highest and lowest contrast sensitivity levels, was
36.2+47.5% (s.d. for the upper end) and 36.2"36.2% (s.d. for the
lower end) for dry AMD versus 89.3621.1% for wet AMD
(p<0.001, GEE). The mean DAG, which expresses the symmetry
between PAG and LAG, was 6.7+15.2% (s.d. for upper end) and
15.2"15.2% (s.d. for lower end) for dry AMD versus 22.6+26.4%
(s.d. for upper end) and 22.6"22.6% (s.d. for lower end) for wet
AMD (p¼0.006, GEE).
Distinguishing dry AMD from wet AMD with 3D-CTAG
Univariate stepwise logistic regression analyses were performed
to distinguish wet AMD from dry AMD. The results of multiple
logistic regression analysis using stepwise selection are shown in
table 3. There was a high speciﬁcity for the presence of a ‘step’ in
wet AMD, deﬁned as a cylindrical defect at low contrast sensi-
tivity levels with a larger cylindrical defect at higher contrast
sensitivity levels (94.1%), and the presence of more than one
3D-CTAG defect (97.1%). These ﬁndings each had a low sensi-
tivity resulting in low predictive values. When stepwise selec-
tion was employed for wet AMD, the presence of more than
one defect, the presence of a ‘step’, and a ‘hill-of-vision’ volume
loss of less than 2% resulted in a high sensitivity (89.7%),
speciﬁcity (85.3%), positive predictive value (83.9%) and negative
predictive value (90.6%).
DISCUSSION
When compared with traditional paper Amsler grid testing,
3D-CTAG had a higher likelihood of detecting central VF
abnormalities in AMD. In dry AMD the sensitivity increased
from 26% to 41%, while in wet AMD it increased from 79% to
100%. This study therefore suggests that similar to the ﬁndings
in glaucoma,13 3D-CTAG increases the ability to detect VF
abnormalities in AMD compared with the traditional paper
Amsler grid.
3D-CTAG detected qualitative and quantitative differences in
the central VF abnormalities of patients with dry AMD
compared with wet AMD. In contrast to dry AMD, wet AMD
displayed a larger abnormality at lower contrast levels than at
higher contrast levels. Nazemi et al16 qualitatively described dry
AMD central visual defects as having a steeper slope and wet
AMD defects as having a shallower slope, which is consistent
with our ﬁndings. However, those studies did not undertake an
in-depth quantitative analysis of either dry or wet AMD. As
Figure 1 Comparison of central visual field abnormality detection rates
between traditional paper Amsler grid and the three-dimensional
contrast threshold Amsler grid (3D-CTAG) in dry and wet age-related
macular degeneration (AMD).
Figure 2 Three-dimensional contrast
threshold Amsler grid (3D-CTAG) plot of
central visual field abnormality in dry
age-related macular degeneration
(AMD). A uniform (ie, same area of
abnormality present at all contrast
sensitivity levels) cylindrical central
visual field abnormality such as this
was found in 12/14 (86%) eyes with dry
AMD.
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reported herein, the DAG (difference between the preserved area
grade and the lost area grade) is a quantitative index of central
VF defects that is useful in distinguishing wet AMD from dry
AMD. As described, 3D-CTAG abnormalities in dry AMD
characteristically presented as cylindrical defects, and thus had
a DAG approaching zero. This was found in all dry AMD eyes
tested. Wet AMD eyes demonstrated larger central VF defects at
lower contrast levels, with a ‘step’ at intermediate and higher
contrast levels. This resulted in DAG measurements in wet
AMD eyes that were three-fold higher than in dry AMD eyes
(p<0.01).
Since this study found a positive predictive value of 83.9% and
negative predictive value of 90.6%, combining the qualitative
ﬁndings with quantitative indices of 3D-CTAG testing into
a diagnostic algorithm for the detection of wet AMD has
potential utility in screening for wet AMD in various healthcare
settings. 3D-CTAG also has the beneﬁt of ease of use with
minimal technological requirements. The only task a patient is
asked to perform is to trace the delineation of distortions on an
Amsler grid with their index ﬁnger while maintaining ﬁxation;
a computer mouse is not involved. 3D-CTAG has the added
advantage over standard-automated perimetry tests, such as the
Humphrey VF analyser, of being able to utilise either central
vision or peripheral vision for ﬁxation. While it is true that
AMD is likely to cause unstable ﬁxation in standard automated
perimetry devices with a central ﬁxation marker in an otherwise
isotropic hemisphere (cupola), the 3D-CTAG features the use of
a rectangular screen with four distinct corners in addition to the
central ﬁxation marker. This allows the subject to maintain
ﬁxation with their peripheral, preserved vision.16
In addition, 3D-CTAG is quick and non-invasive, thus miti-
gating a learning effect and fatigue inherent to all VF testing. This
is particularly true in patients undergoing Humphrey VF testing
on both eyes, with average time of testing of up to 8 min per
eye.20 Our average testing time per eye, including using the ﬁve
contrast sensitive threshold values, was less than 5 min per eye.
A concern in VF testing for glaucoma is the masking of
a defect secondary to the Troxler effect. However, in our
previous study12 an enlarged blind spot was detected with 3D-
CTAG, even though the physiological blind spot is not detected
in this test. Hence, despite the usual problem with Troxler
suppression of arcuate scotomas in glaucoma, we are able to
Figure 3 Three-dimensional contrast
threshold Amsler grid (3D-CTAG) plot of
central visual field abnormality in wet
age-related macular degeneration
(AMD). There is a non-uniform
cylindrical abnormality; that is large
area of abnormality at high contrast
sensitivity levels with a distinct ‘step’ at
lower contrast sensitivity level. This
‘step’ abnormality was found in 16/28
(51%) of eyes with wet AMD.
Table 3 Univariate logistic regression (adjusted for the correlation between eyes within patients) for wet age-related macular degeneration (AMD)
using stepwise selection
OR (95% CI) p Value Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%)
Number of A/G defects 35.09 (2.18 to 565.1) 0.01 e e e e
Hill-of-vision % volume lost 5.79 (0.003 to 9799) 0.64 e e e e
LAG 1.03 (1.01 to 1.04) <0.001 e e e e
LAG $45.3 5.44 (1.95 to 15.18) 0.001 72.4 67.6 65.6 74.2
PAG 1.03 (1.02 to 1.04) <0.001 e e e e
PAG $96.9* 3.99 (1.43 to 11.16) 0.008 69.0 64.7 62.5 71.0
DAG 1.06 (1.01 to 1.12) 0.03 e e e e
DAG >0* 4.16 (1.41 to 12.27) 0.01 62.1 70.6 64.3 68.6
Total slope 1.03 (1.02 to 1.04) <0.001 e e e e
LogMAR 14.20 (1.79 to 112.9) 0.01 e e e e
Scotoma shape¼Step 21.00 (2.99 to 147.6) 0.002 55.2 94.1 88.9 71.1
Number of defects >1 5.12 (0.43 to 61.69) 0.20 13.8 97.1 80.0 56.9
Step and >1 defect 20.33 (4.76 to 86.73) <0.001 66.5 91.2 86.4 75.6
Hill-of-vision % volume lost >0 and <2 9.60 (2.14 to 43.09) 0.003 51.7 88.2 78.9 68.2
Step and >1 defect and hill-of-vision %
volume lost >0 and <2
51.12 (10.42 to 250.7) <0.001 89.7 85.3 83.9 90.6
‘Step’ indicates a cylindrical defect at high contrast levels with a larger cylindrical defect at lower contrast levels.
*Median value of sample.
A/G, Amsler grid defect using 3D-CTAG; DAG, difference area grade; LAG, lost area grade; LogMAR, logarithm of the minimum angle of resolution; PAG, preserved area grade.
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consistently ﬁnd and characterise these VF defects. It appears,
therefore, that all scotomas in VF areas that are represented in
the visual cortex can be detected by 3D-CTAG.
Thus, future studies should be undertaken to evaluate
3D-CTAG testing in a prospective health screening setting.
Future studies could also address a potential weakness of the
present study, including subjects who were either normal
(n¼27) or had one of two diseases, that is dry (n¼34) or wet
(n¼29) AMD, as well as not including fellow eyes from patients
with bilateral pathology. A control group with similar VA but no
macular disease should also be examined. Future studies might
also include other maculopathies in the study population. If
these studies conﬁrm the use of 3D-CTAG testing in AMD, then
subsequent studies could use 3D-CTAG to assess the efﬁcacy of
therapy for wet AMD. Studies might also be undertaken to
compare 3D-CTAG with microperimetry, which evaluates set
points in the central VF, polarisation-sensitive OCT, which has
shown promise in identifying retinal pigment epithelium (RPE)
disease, and preferential hyperacuity perimeter, which has
similarly been shown to be superior to traditional paper Amsler
grid testing.21e24
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